Automated proton planning reproduced clinical head and neck NTCP estimates within minutes
Automated proton plans reproduced clinical dysphagia and xerostomia estimates closely while reducing optimization time from days to about one hour.
Automated proton plans reproduced clinical dysphagia and xerostomia estimates closely while reducing optimization time from days to about one hour.
Ultra-high dose-rate protons produced fewer DNA breaks at low scavenger concentration, but the effect diminished or reversed under other experimental conditions.
Five-year local control exceeded 89% across proton, photon and stereotactic approaches, with no significant modality effect in meta-regression.
Mean heart dose increased during esophageal IMPT, while heart-dose–triggered replanning reduced the excess dose in patients requiring adaptation.
More than 56,000 theoretically eligible European patients lived in areas with no proton access or critical capacity shortages in 2025.
Automated pediatric CSI contours achieved a mean Dice score of 0.959 and reduced target-delineation time from approximately eight hours to 30 minutes.
COMPPARE enrolled 2,524 patients from 51 institutions in 52 months, with Black participation reaching 16% of the cohort.
Adaptation would have improved organ sparing or target coverage in 46% of fractions, with a median workflow time of 61.9 minutes.
TLD-100 over-responded below 7 Gy/s and under-responded above 300 Gy/s, despite remaining dose-independent from 3 to 18 Gy.
Proton therapy produced greater CT-detected lung changes than photons despite lower lung dose and no increase in clinical pulmonary toxicity.
Radiographic brain injury occurred in 16% of children, all asymptomatic; every affected patient had received high-dose chemotherapy.
Automated dose-guided positioning matched anatomical alignment overall and improved primary target coverage by 1.0% when the clinical goal was initially missed.
Preclinical lung studies support normal-tissue sparing, but uncertain biological thresholds, dose conformity, and respiratory motion still prevent clinical implementation.
Proton plans preserved 20-Gy target coverage while reducing spinal cord, oesophageal, lung, and bowel dose compared with photon VMAT.
Temporal lobe volumes receiving high dose or moderate dose with high LET jointly predicted grade 2 or higher necrosis.